Introduction
Accelerated atherosclerosis is a leading cause of increased cardiovascular morbidity and mortality in peritoneal dialysis (PD) patients. Traditional factors such as hypertension, hyperlipidemia, diabetes, smoking, and advanced age are thought to contribute to accelerated atherosclerosis. However, the exact mechanisms responsible for this accelerated development of atherosclerosis have remained elusive. Novel risk factors, such as excess production of reactive oxygen species (ROS), endothelial dysfunction and inflammation have been increasingly associated with this process [1, 2] .
Increased oxidative stress (OS) and endothelial dysfunction have been recently suggested to be key factors in the pathogenesis and development of atherosclerosis in end-stage renal disease (ESRD) patients [3] . Oxidative stress is the result of an imbalance between generation and removing of reactive oxygen species. Disturbances in the normal redox state of cells can cause toxic effects through the production of peroxides and free radicals that damage all components of the cell, including proteins, lipids, and DNA. Endothelial dysfunction is an early initiated event in atherosclerosis as well as a risk factor for future cardiovascular disease. The presence of increased OS and endothelial dysfunction in ESRD patients has been demonstrated by many studies and oxidative stress, by causing NO breakdown, can be a major mechanism of endothelial dysfunction. However, very few studies have been performed to investigate the role of these important nontraditional factors in accelerated atherosclerosis among PD patients.
To delineate the effects of oxidative stress and endothelial dysfunction on the atherosclerosis in PD patients, we assessed the levels of plasma 8-OHdG, ET-1, and eNOS activities as well as carotid intima-media thickness (CIMT) to determine the association of oxidative stress, endothelial dysfunction and accelerated atherosclerosis. Our findings not only clearly identify oxidative stress and endothelial dysfunction as the key players in the development of accelerated atherosclerosis but also suggest antioxidant therapy may reduce the incidence of cardiovascular disease in PD patients.
Materials and Methods

Subjects
This was a cross-sectional, cohort, comparison study and conducted at the Second Hospital of Hebei Medical University in Shijiazhuang, China. The study was approved by the Ethics Committee on Human Research at Second Hospital of Hebei Medical University. All study subjects signed a written, informed consent prior to enrollment. Eighty PD patients with ESRD and being on PD for more than 6 months (aged 41.6±14.03 years; 24 men and 56 women) as well as 12 age-and sex-matched healthy controls free from any signs of chronic disease after clinical examination and laboratory checkup (aged 40.92±5.32; 5 men and 7 women) participated in the study. All PD patients were performing 4 h 2 L exchanges per day dialysis with standard acidic, lactate-based glucose dialysis solution. They were on the Baxter Twin Bag system. Dwell times were generally 4-6h during the day. All study subjects were non-smokers and did not consume alcohol regularly. None of the subjects received antibiotics, corticosteroids, anti-inflammatory drugs, cytotoxic drugs and vitamins during the study. Kt/V was adopted to evaluate the dialysis adequacy.
Exclusion criteria: patients with any systemic illness such as diabetes, malignancy, lupus, vasculitis were excluded. Patients with intravenous iron treatment or with any infection disease in the past month were also excluded.
Laboratory Examinations
Measurement of plasma 8-hydroxydeoxyguanosine (8-OHdG) levels 8-OHdG levels were measured by using a competitive in vitro enzyme-linked immunosorbent assay (ELISA) kit (Bioxytech, OXIS Health Products, Inc., Portland, OR, USA) according to the manufacture's protocol. In brief, 50μl plasma sample and 50μl of reconstituted primary antibody were added to each well of 8-OHdGcoated microtitre plates and incubated at 37°C for 1 h. Plates were washed three times with phosphate-buffered saline (PBS) followed by adding horseradish peroxidase-conjugated secondary antibody. After incubation at 37°C for another hour, unbound secondary antibody was removed, and the plate was washed again three times. The amount of antibody bound to the plate was determined by the development of color intensity after the addition of substrate containing 3,3,5, ′-tetramethyl-benzidine using a computer-controlled spectrophotometric plate reader at the wavelength of 450 nm. The concentration of 8-OHdG was interpolated from a standard curve. The detection range of the ELISA assay was 0.5-200ng/ml.
Measurement of plasma Endothelin-1 levels
Plasma ET-1 concentrations were determined by use of a radioimmunoassay kit (Beijing North Institute of Biotechnology, Beijing, China) according to its manufacture's protocol. In short, 100μl of plasma sample were added into duplicate tubes followed by adding primary antibody. After incubation for 16-24 hours at 4°C, 100μl of 125I-peptide tracer solution were added followed by incubation for 16-24 hours at 4°C. Then the tubes were incubated for 90 minutes at room temperature after adding Goat Anti-Rabbit IgG serum and normal Rabbit serum. Tubes were centrifuged at 1700xg for 20 minutes at 4°C. All the supernatants were carefully removed immediately following centrifugation. Counts Per Minute (Cpm) of all the pellets were counted by using a γ -counter. Plasma ET-1 concentrations were calculated from the stand curve. The detection range of the RIA assay was 10-1280pg/ml.
Measurement of plasma endothelial nitric oxide synthase activity
Plasma eNOS activities were measured using colorimetric nitrate reductase assay by Nanjing Jiancheng Biochemical Co (Nanjing, China).
Measurement of carotid artery intimal-medial thickness
Quantitative ultrasound measurements for both sides of carotid artery intimal thickness were performed using ATL HDI 5000 SonoCT/XRES Color Doppler System (Bothell, WA) by a single expert sonographer. The sonographer was blinded to the subject's identity.
Astandard protocol [4] , scanning the near and far walls of the right and left common, internal and external carotid arteries, and bifurcations in three different projections (anterior, lateral, and posterior), was performed. Eight segments of the right and left carotid arteries in each projection were examined, and the 48 CIMT measurements were averaged to calculate the average CIMT for each subject. The carotid artery thickness is defined as CIMT≥1.0mm at carotid sinus below 10cm and/or CIMT≥1.2mm at the carotid bifurcation according to the standard of AHA (American Heart Association). The subjects were assigned to two groups after CIMT measurement: those who did not have atherosclerosis (CIMT<1.0mm) and those who had atherosclerosis (CIMT≥1.0mm and/or plaque formation).
Statistical analysis
Age, sex, medications, blood pressure, hemoglobin (Hb), albumin, cholesterol, Calcium (Ca), phosphate (Phos), blood urea nitrogen (BUN) and serum creatinine (Scr) were recorded. Clinical characteristics were reported as means ± standard deviations for continuous variables and frequencies for categorical variables. Statistical analysis was performed on SPSS (IBM, Armonk, NY) version 13.0. Differences between the groups were examined by one-way ANOVA or unpaired Student′s t-test when necessary and chi-square tests for continuous and categorical variables, respectively. A multiple linear regression analysis was used to determine the independent predictor of CIMT. Results with p<0.05 were considered statistically significant in all analyses. patients than that in their counterparts (39.33±9.34ng/ml vs 7.25 ±0.97ng/ml, 139.35±31.12pg/ml vs 16.00±1.41pg/ml, respectively P < 0.01, Fig 1) . Further analysis showed that the levels of plasma 8-OHdG and ET-1 in PD patients with carotid atherosclerosis dramatically increased compared to those without carotid atherosclerosis (42.83±7.70ng/ml vs 28.07±3.15ng/ml and 147.97±28.49pg/ml vs 111.69±22.05pg/ml respectively, P<0.01). On the other hand, plasma eNOS activities were significantly decreased in PD patients than in control group (12.57±1.76u/ml vs 14.25±1.86u/ml, P < 0.01, Fig 1) . Similarly, PD patients with atherosclerosis showed statistically lower eNOS activities than those without (12.14±1.52u/ml vs 13.96±1.80u/ml, P<0.01). 
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Correlation analysis
Linear regression analysis was performed to identify the correlations between characteristics of patients, CIMT and the levels of plasma 8-OHdG, ET-1 and eNOS activities. The levels of plasma 8-OHdG in PD patients were correlated positively with ET-1 as well as CIMT, and the correlation was statistically significant (P<0.01, Fig 2) . In addition, the levels of plasma 8-OHdG had significant positive correlations with age (r=0.697, P=0.000), dialysis duration (r=0.752, P=0.000), hsCRP (r=0.532, P=0.000), systolic blood pressure(r=0.350, P=0.001), diastolic blood pressure (r=0.269, P=0.000), while negative correlation with eNOS (r=-0.723, P=0.000), KT/V (r=-0.367, P=0.001), but without any correlation with ALB, Hb, Scr, BUN, CHOL, Ca, or Phos (P>0.05).
The levels of plasma ET-1 in PD patients were positively correlated with age (r=0.639, P=0.000), dialysis duration (r=0.569, P=0.000), hsCRP (r=0.438, P=0.000), systolic blood pressure (r=0.364, P =0.001), diastolic blood pressure (r=0.280, P=0.002), CIMT (r=0.585, P=0.000), 8-OHdG (r=0.753, P=0.000), but negatively correlated with KT/V (r=-0.285, P=0.010), eNOS activity (r=-0.646, P=0.000). There was no correlation between plasma ET-1 levels and ALB, Hb, Scr, BUN, CHOL, Ca, or Phos (P> 0.05).
The levels of plasma eNOS in PD patients were negatively correlated with age (r=-0.656, P=0.000), dialysis duration (r=-0.599, 
Discussion
Chronic renal disease is associated with accelerated cardiovascular risk and the cardiovascular diseases are the most common cause of morbidity and mortality in PD patients [5] . It is well known that accelerated atherosclerosis (AS) is one of the major factors associated with morbidity and mortality of cardiovascular disease. Studies have shown that thickened carotid intima-media thickness is an early independent predictor in ESRD patients and may be used to 
predict the risk of cardiovascular events [6] . We found that the morbility of carotid artery atherosclerosis is as high as 76.25% in ESRD patients receiving maintenance peritoneal dialysis, suggesting that patients receiving peritoneal dialysis may have a higher risk of cardiovascular diseases. This finding is supported by Guo's report [7] which showed that 69.09% patients receiving maintenance hemodialysis had carotid plaques.
Increased oxidative stress has been shown in patients treated with continuous ambulatory peritoneal dialysis (CAPD) by Boudouris et al [8] . Oxidative stress is now considered as one of the most important pathogenetic mediator of atherosclerosis among non-traditional cardiovascular risk factors. In addition, oxidative stress also contributes to the ultrafiltration failure [8, 9] of peritoneal membrane. However, factors caused the increase of oxidative stress in PD patients are unclear. 8-OHdG is the special metabolic end product of DNA oxidative damage and is universally acknowledged as a new type of sensitive biomarkers for evaluation oxidative stress in the body. Our research shows that plasma 8-OHdG levels increased significantly in peritoneal dialysis patients compared to those in the control group, which were about as 5.4 times high as those in the control group. The plasma 8-OHdG levels were also positively correlated with age, systolic pressure, diastolic pressure and hs-CRP. Previous study [7] demonstrated that 8 -OHdG levels increased in the ESRD patients receiving maintenance hemodialysis and our data suggest this phenomenon also exists in peritoneal dialysis patients. Moreover, oxidative stress is closely associated with the inflammation of patients with peritoneal dialysis and high blood pressure. Oxidative stress has also been shown being an independent risk factor of high systolic and diastolic blood pressure in patients with peritoneal dialysis [10, 11] . It is very likely that the inflammatory process induces oxidative stress and oxidative stress enhances inflammatory reaction. It has been suggested that both the inflammation and oxidative stress involved in the pathogenesis of high blood pressure while hypertension itself or factors associated with hypertension such as fluid retention aggravate the oxidative stress in PD patients. The synergetic effects of oxidative stress and hypertension further lead to the failure of peritoneal membrane.
It has been well documented that oxidative stress and vascular endothelial dysfunction are common features of patients with chronic kidney disease (CKD) [12, 13] . This study demonstrated that PD patients still exhibit endothelial dysfunction given that the plasma levels of ET-1 increased significantly while eNOS activities reduced dramatically in these patients. This result suggests dialysis itself is not enough to block the progression of chronic kidney diseases and novel therapy against oxidative stress needs to be developed. The exact pathogenesis of endothelial dysfunction in patients with ESRD is unclear but oxidative stress plays the leading role in vascular endothelial cell damage, the initiation and development of endothelial dysfunction in addition to many other factors, such as high blood pressure, high blood sugar, the accumulation of toxin, lipid metabolic disorder, and inflammation [14] .
Interestingly, Malik et al [15] has shown that oxidative stress is one of the critical factors in the pathogenesis of atherosclerosis. Further study demonstrated that plasma levels of oxidative stress marker 8-OHdG in hemodialysis patients were positively correlated with CIMT and it is possible to be adopted as one of the subclinical predictors for atherosclerosis [16] . Our results and other report [17] showed that, oxidative stress indicated by 8-OHdG or ADMA levels is the independent risk factor of CIMT in PD patients. It has been reported that peritoneal dialysis patients exhibit vascular endothelial dysfunction even those there was no evidence of atherosclerosis disease [3] . Our study also demonstrated that CIMT positively correlated with 8-OHdG in PD patients, and the plasma 8-OHdG levels were significant higher in PD patients with arterial stiffness than those without. The plasma levels of 8-OHdG statistically associated with ET-1 and eNOS activities in PD patients, which indicate that oxidative stress and endothelial dysfunction play a critical role in the development of cardiovascular disease in PD patients. Our results that the endothelial dysfunction in PD patients positively correlated with CIMT support the idea that the endothelial dysfunction is an early sign of atherosclerosis.
There are a number of limitations to our study. The small sample size may limit the applicability of the findings to larger population-level cohorts. Given the cross-sectional study, the progress of oxidative stress has not been observed during peritoneal dialysis. Therefore, potential non-sustained events may have been counted, altering the power of the oxidative stress marker for prediction atherosclerosis.
In summary, PD patients have significant higher oxidative stress, greater endothelial dysfunction, and increased atherosclerosis. These abnormalities are closely associated with each other and enhance the process of atherosclerosis development. Oxidative stress participates in the occurrence and development of the vascular endothelial dysfunction, leading to the initiation of atherosclerosis in PD patients. Plasma 8-OHdG, an oxidative stress marker, is an independently risk factors for atherosclerosis in PD patients. Further study should be conducted to evaluate antioxidant therapy in ESRD patients receiving CAPD to test if antioxidant drugs protect the vascular endothelial function, reduce the incidence of cardiovascular diseases, and improve the survival rate in PD patients.
